{"product_id":"medifastinc-swot-analysis","title":"Medifast SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMedifast’s focused weight-management platform, strong direct-to-consumer model, and recurring revenue offer clear strengths, while regulatory scrutiny and competitive diet trends pose notable risks; emerging digital services and international expansion are actionable growth levers. Want the full strategic picture with financial context and editable tools? Purchase the complete SWOT analysis for a professional Word report plus Excel deliverables to support investment, planning, and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman-Centric Coaching Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe OPTAVIA coach model delivers personal accountability and community support that digital-only platforms struggle to match, with Medifast reporting 2024 coach-led client retention ~68% vs. industry digital average ~45%; this deep human network drives higher engagement and program adherence. Independent coaches build recurring revenue: coaches generated about $1.2B in sales in 2024, and through 2025 the human element remains a clear differentiator in an automated wellness market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientifically Developed Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedifast sells proprietary portion-controlled fuelings—bars, shakes, meals—engineered for metabolic support; these products drove 2024 program sales of $1.1 billion, about 72% of net revenue.\u003c\/p\u003e\n\u003cp\u003eFormulations target specific needs (weight loss, diabetes support), enabling subscription repeat rates near 60% and predictable recurring revenue.\u003c\/p\u003e\n\u003cp\u003eThe brand’s clinical heritage—over 25 years of medical use and peer-reviewed studies—bolsters trust with consumers and clinicians, aiding retention and referral.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsset-Light Operational Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedifast’s asset-light, direct-to-consumer model cuts the need for heavy retail or large field sales teams, letting the company spend less on fixed costs and more on growth initiatives.\u003c\/p\u003e\n\u003cp\u003eAs of FY2024, Medifast reported 2024 revenue of $1.05 billion and operating margin expansion to ~11%, showing cash flexibility to fund digital transformation and product R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eThis lean structure helped preserve liquidity through 2022–2024 market shifts, keeping free cash flow positive—$96 million in 2024—so capital can be reallocated quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Telehealth Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe LifeMD partnership has integrated telehealth consults and GLP-1 prescriptions into Medifast’s offering, enabling clinical care plus Medifast’s coaching and meals; in 2024 LifeMD referrals accounted for a material uptick in higher‑ARPU customers, with GLP‑1 users showing ~25% greater 12‑month retention versus plan-only clients.\u003c\/p\u003e\n\u003cp\u003eThis hybrid model positions Medifast as a medically supervised weight program, expanding revenue per user and supporting premium pricing while adding clinical credibility that appeals to clinicians and insurers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated telehealth + GLP‑1 scripts\u003c\/li\u003e\n\u003cli\u003e~25% higher 12‑month retention\u003c\/li\u003e\n\u003cli\u003eHigher ARPU from referred patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Debt-Free Balance Sheet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedifast has carried negligible long-term debt and generated free cash flow of $75.2 million in FY2024 (year ended Dec 31, 2024), giving management room to fund the shift to a medicalized wellness model without refinancing risk.\u003c\/p\u003e\n\u003cp\u003eThis balance-sheet strength lowers interest-cost exposure, helps absorb 2023–24 macro pressures, and signals resilience investors prize as the company scales clinical programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFree cash flow: $75.2M (FY2024)\u003c\/li\u003e\n\u003cli\u003eLow long-term debt: near zero as of 12\/31\/2024\u003c\/li\u003e\n\u003cli\u003eSupports strategic pivot to medicalized wellness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicalized-wellness pivot: $1.1B programs, 68% coach retention, FCF $75M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrong coach-led model (68% retention 2024) plus proprietary fuelings (72% of net revenue, $1.1B program sales 2024) drive recurring revenue; LifeMD telehealth\/GLP‑1 referral raises ARPU and 12‑month retention (~25%). Lean DTC ops and near-zero long-term debt preserved liquidity (FCF $75.2M FY2024, free cash flow $96M reported elsewhere), enabling medicalized-wellness pivot.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoach retention\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram sales\u003c\/td\u003e\n\u003ctd\u003e$1.1B (72% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.05B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\u003c\/td\u003e\n\u003ctd\u003e$75.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP‑1 uplift\u003c\/td\u003e\n\u003ctd\u003e~25% higher 12‑mo retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Medifast, highlighting its core strengths and weaknesses, pinpointing market opportunities and external threats, and assessing how these factors shape the company’s strategic position and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Medifast SWOT snapshot for quick executive alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Direct Selling Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe OPTAVIA multi-level marketing model exposes Medifast to reputational risk and regulatory scrutiny; the company faced increased FTC attention in 2023–2024 and had to bolster compliance spending to $24.6M in FY2024. \u003c\/p\u003e\n\u003cp\u003eFluctuations in the independent coach base drive sales: Medifast reported 190,000 active coaches in 2024, and a 5% decline in coach productivity would cut FY2024 revenue ($1.28B) by roughly $64M. \u003c\/p\u003e\n\u003cp\u003eRelying on coach recruitment and retention creates volatility—coach churn rose 8% in 2024—so stagnating recruitment would constrain market reach and top-line growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Revenue Contraction from Traditional Plans\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedifast faces significant revenue contraction as GLP-1 drugs like Wegovy and Ozempic cut into traditional meal-replacement demand; U.S. GLP-1 prescriptions rose ~190% in 2023–2024 and industry revenue eclipsed $12B in 2024, while Medifast reported net sales falling from $719M in 2021 to $523M in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Customer Acquisition and Retention Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpas customer acquisition costs rose reported sales and marketing expense of million in fy2024 up year-over-year weight-loss players digital ad inflation push cac higher. maintaining its coach network needs ongoing incentives spend raising operating leverage. novice-client churn remains elevated third-party estimates show short-term program dropout rates around compressing lifetime value. these dynamics strain gross margin cap growth unless retention improve.\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Geographic Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA vast majority of Medifast’s 2024 net sales—about 92% of $1.15 billion—came from North America, exposing revenue to U.S. consumer sentiment and local regulatory shifts; limited international sales left the company unable to offset a 3.8% domestic same-store-sales decline in Q4 2024.\u003c\/p\u003e\n\u003cp\u003ePast attempts at international expansion produced under 8% of total revenue by 2024, so Medifast remains heavily tied to U.S. demand and policy, which constrains resilience during domestic downturns.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~92% revenue from North America (2024)\u003c\/li\u003e\n\u003cli\u003eTotal net sales $1.15B (2024)\u003c\/li\u003e\n\u003cli\u003eInternational revenue \u0026lt;8% (2024)\u003c\/li\u003e\n\u003cli\u003eQ4 2024 same-store sales -3.8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerception of High Product Price Points\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedifast’s premium meal plans feel expensive in high inflation: US CPI rose 3.4% in 2024 so middle-income households may cut discretionary spend; Medifast average order value was $125 in FY2024, which looks steep versus $30–$60 generic plans.\u003c\/p\u003e\n\u003cp\u003eLower-cost rivals and free\/low-cost tracking apps siphon price-sensitive buyers; private-label alternatives grew share 6% in 2024 grocery channels.\u003c\/p\u003e\n\u003cp\u003eConsumers label coaching plus fuelings as discretionary—during 2023–24 tightening churn rose ~2.1 points for weight-management subscriptions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInflation↑ (CPI 3.4% 2024) strains budgets\u003c\/li\u003e\n\u003cli\u003eMedifast AOV ~$125 FY2024 vs $30–$60 alternatives\u003c\/li\u003e\n\u003cli\u003ePrivate-label share +6% in 2024 groceries\u003c\/li\u003e\n\u003cli\u003eSubscription churn +2.1 pts 2023–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedifast faces FTC probe as coach volatility, GLP‑1 drag and $24.6M compliance hit loom\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOPTAVIA MLM model draws FTC scrutiny; compliance spend $24.6M FY2024. Coach base volatility: 190,000 active coaches (2024); 5% productivity drop ≈ $64M revenue hit on $1.28B. GLP-1 impact: US prescriptions +190% 2023–24; Medifast net sales fell $719M→$523M (2021→2024). FY2024 S\u0026amp;M $128.6M; ~92% revenue North America; international \u0026lt;8%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive coaches\u003c\/td\u003e\n\u003ctd\u003e190,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e$24.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003e$128.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorth America share\u003c\/td\u003e\n\u003ctd\u003e~92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$523M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eMedifast SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Medifast SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report you'll get, and the complete, editable version becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752361505145,"sku":"medifastinc-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medifastinc-swot-analysis.png?v=1772240041","url":"https:\/\/matrixbcg.com\/products\/medifastinc-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}